- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07949916
Immunogenicity and Safety of Vaccination Against Tick Borne Encephalitis (TBE) in Patients Living With Multiple Sclerosis (MS) (MS and TBE vac)
This is a monocenter, prospective cohort study. The study investigates the response of patients living with multiple sclerosis (MS) to vaccination against tick-borne viral encephalitis (TBE).
The prevalence of TBE has increased significantly in Switzerland over the past two decades. Whereas previously only the lowland regions of northern Switzerland and the Aare Valley were considered areas where TBE vaccination was indicated, the disease is now endemic throughout Switzerland (except for Ticino). Since TBE specifically affects the nervous system, there is a clear indication for vaccination, particularly for people whose nervous system is already compromised.
MS is the most common neurological autoimmune disease among young adults in northern latitudes. It is a progressive disease characterized by a gradual deterioration of neurological functions. The course of the disease can be slowed through immunomodulatory therapies. However, these therapies also lead to a certain degree of immunosuppression, which may reduce the immune response to vaccinations. At the same time, some people with MS experience fear or scepticism towards vaccinations, as infections often lead to a worsening of symptoms or can trigger a relapse. Since vaccinations mimic an infection to some extent, this concern is sometimes transferred to vaccinations as well.
The study hypothesizes that the TBE vaccine in people living with MS on non-B-cell depleting treatment shows adequate immunogenicity.
Moreover, the study will assess the safety of TBE vaccination.
Studie Overzicht
Toestand
Conditie
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Cornelia Staehelin, PD. Dr. med.
- Telefoonnummer: +41 31 632 01 83
- E-mail: cornelia.staehelin@insel.ch
Studie Contact Back-up
- Naam: Robert Hoepner, Prof. Dr. med.
- Telefoonnummer: +41 316325835
- E-mail: robert.hoepner@insel.ch
Studie Locaties
-
-
-
Bern, Zwitserland, 3010
- Werving
- University Hospital of Bern
-
Contact:
- Cornelia Staehelin, PD Dr. med
- Telefoonnummer: +41 31 632 01 83
- E-mail: cornelia.staehelin@insel.ch
-
Contact:
- Robert Hoepner, PD Dr. med.
- Telefoonnummer: +41 +41 632 60 93
- E-mail: robert.hoepner@insel.ch
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
The investigators target a sample size of 50 people living with MS with stable RRMS (no evidence of disease activity -NEDA-3 status - as defined by no clinical relapse, no EDSS worsening and no new MS-lesions on MRI) for ≥ 1 year prior to inclusion into the study and treated with non-B-cell depleting therapies for at least 6 months in monotherapy.
In order to have a homogenous and stable patient population, the investigators decided to include only patients without evidence of disease activity for at least 1 year prior to inclusion. Considering the latter the investigators classify any disease reactivation during the period of 42 days (+/- 7days) after the first dose / booster dose as related to the intervention (vaccination).
Beschrijving
Inclusion Criteria
-
Adult (≥ 18 years old)
-
Suspected neuroimmunological disorder with CNS affection
- including suspicion of Multiple Sclerosis (MS)
- Diagnosed Multiple Sclerosis (MS)
- Clinically Isolated Syndrome
- Radiologically Isolated Syndrome
-
stable RRMS - defined as no evidence of disease activity-NEDA-3 status-as defined by no clinical relapse, no EDSS worsening and no new MS-lesions on MRI for ≥ 1 year prior to inclusion
-
treated with non-B-cell depleting therapies for at least 6 months in monotherapy
-
TBE vaccine:
- never been vaccinated against TBE or
- clinical indication for booster vaccination (person living with MS and has had primary series of 3 vaccines of which the last one was ≥ 10 years ago)
-
Provided written informed consent
Exclusion Criteria
- Any B-cell depleting therapies in last 12 months prior to recruitment
- Any other vaccination in last 2 months prior to recruitment
- Any foreseeable and necessary other vaccination up to 42 days post dose 1
- Immunoglobulin-Infusion (intravenous or subcutaneous, IVIG or SCIG) in the last 4 months prior to the drawing of study samples
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: PROSPECTIVE
Cohorten en interventies
Groep / Cohort |
|---|
|
Primary vaccination series or Booser against TBE in patients with MS
According to Swiss guidelines, patients with MS will receive the primary vaccination series (3 doses) against TBE (if they have never been vaccinated) or a TBE booster (if they have already received the primary vaccination series and their last vaccination was ≥ 10 years ago). |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Primary immunogenicity endpoint
Tijdsspanne: 42 days post dose 1
|
Change in antibody concentration (GMC) from baseline to day 42 post dose 1 as measured by ELISA |
42 days post dose 1
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Immunogenicity endpoint
Tijdsspanne: 42 days post dose 1
|
Change in antibody titers as measured by serum neutralizing test (SNT) from baseline to day 42 (post dose 1) |
42 days post dose 1
|
|
Immunogenicity endpoint
Tijdsspanne: 7 months post dose 1 or 6 months post booster dose
|
Change in antibody titers as measured by ELISA from baseline to week 9 and month 7 post dose 1 if primary vaccination resp. from baseline to month 6 post booster dose. |
7 months post dose 1 or 6 months post booster dose
|
|
Immunogenicity endpoint
Tijdsspanne: 7 months post dose 1 or 6 months post booster dose
|
Change in antibody titers as measured by SNT from baseline to week 9 and month 7 post dose 1 if primary vaccination resp. from baseline to month 6 post booster dose. |
7 months post dose 1 or 6 months post booster dose
|
|
Immunogenicity endpoint
Tijdsspanne: at each time point (7 months)
|
Seropositivity as measured by ELISA . Seropositivity is defined as IgG antibody concentration >150 U/ml for ELISA. |
at each time point (7 months)
|
|
Immunogenicity endpoint
Tijdsspanne: at each time point (7 months)
|
Seropositivity as measured by SNT at each time point. Seropositivity is defined as antibody titer >1:10 for SNT. |
at each time point (7 months)
|
|
Safety endpoint
Tijdsspanne: 42 (+/-7d) post dose 1
|
The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1 - Incidence of MS-relapses - defined clinically, according to clinical expert judgement, by the presence of MS-typical symptoms with objectifiable findings lasting more than 24 hours, without fever or infection. |
42 (+/-7d) post dose 1
|
|
Safety endpoint
Tijdsspanne: 42 (+/-7d) post dose 1
|
The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1 - Activity in cerebral MRI scan (new or enlarging lesions or gadolinium uptake) |
42 (+/-7d) post dose 1
|
|
Safety endpoint
Tijdsspanne: 42 (+/-7d) post dose 1
|
The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1 - Neurological assessment (EDSS) |
42 (+/-7d) post dose 1
|
|
Safety endpoint
Tijdsspanne: 42 (+/-7d) post dose 1
|
The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1 - Multivariable blood biomarker based scores for MS disease activity (MSDA) and disease pathways (Octave Bioscience, USA) |
42 (+/-7d) post dose 1
|
|
Safety endpoint
Tijdsspanne: 42 (+/-7d) post dose 1
|
The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1 - Vaccine reactogenicity (solicited and unsolicited local and systemic vaccine reactions) |
42 (+/-7d) post dose 1
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Infectieuze encefalitis
- Vector overgedragen ziekten
- Neuro-inflammatoire ziekten
- Hersenziekten
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Auto-immuunziekten
- Ziekten van het immuunsysteem
- Infecties
- RNA-virusinfecties
- Virusziekten
- Demyeliniserende auto-immuunziekten, CZS
- Auto-immuunziekten van het zenuwstelsel
- Demyeliniserende ziekten
- Arbovirus-infecties
- Flavivirus-infecties
- Flaviviridae-infecties
- Door teken overgedragen ziekten
- Encefalitis, viraal
- Virale ziekten van het centrale zenuwstelsel
- Infecties van het centrale zenuwstelsel
- Encefalitis
- Encefalitis, arbovirus
- Multiple sclerose
- Encefalitis, door teken overgedragen
Andere studie-ID-nummers
- 2025-01767
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .